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Abstract  
Sleep is an essential state of decreased activity and alertness but molecular factors 
regulating sleep duration remain unknown. Through genome-wide association analysis in 
446,118 adults of European ancestry from the UK Biobank, we identify 78 loci for self-
reported habitual sleep duration (p<5x10-8; 43 loci at p<6x10-9). Replication is observed 
for PAX8, VRK2, and FBXL12/UBL5/PIN1 loci in the CHARGE study (n=47,180; 
p<6.3x10-4), and 55 signals show sign-concordant effects. The 78 loci further associate 
with accelerometer-derived sleep duration, daytime inactivity, sleep efficiency and 
number of sleep bouts in secondary analysis (n=85,499). Loci are enriched for pathways 
including striatum and subpallium development, mechanosensory response, dopamine 
binding, synaptic neurotransmission and plasticity, among others. Genetic correlation 
indicates shared links with anthropometric, cognitive, metabolic, and psychiatric traits and 
two-sample Mendelian randomization highlights a bidirectional causal link with 
schizophrenia. This work provides insights into the genetic basis for inter-individual 
variation in sleep duration implicating multiple biological pathways. 
  
Introduction 
Sleep is an essential homeostatically-regulated state of decreased activity and alertness 
conserved across animal species, and both short and long sleep duration associate with 
chronic disease and all-cause mortality1,2. Research in model organisms (reviewed in 3,4) 
has delineated aspects of the neural-circuitry of sleep-wake regulation5 and molecular 
components including specific neurotransmitter and neuropeptide systems, intracellular 
signaling molecules, ion channels, circadian clock genes and metabolic and immune 
factors4, and more recently phosphorylation of synaptic proteins6, but their specific roles 
and relevance to human sleep regulation are largely unknown. Prospective epidemiologic 
studies suggest that both short (<6 hours per night) and long (>9 hours per night) habitual 
self-reported sleep duration associate with cognitive and psychiatric, metabolic, 
cardiovascular, and immunological dysfunction as well as all-cause mortality compared 
to sleeping 7-8 hours per night7–9. Furthermore, chronic sleep deprivation in modern 
society may lead to increased errors and accidents10. Yet, whether short or long habitual 
sleep duration causally contributes to disease initiation or progression remains to be 
established. 
 
Habitual self-reported sleep duration is a complex trait with an established genetic 
component (twin- and family-based heritability (h2) estimates =9-45%11–14). Candidate 
gene sequencing in pedigrees and functional validation of rare, missense variants 
established BHLHE41 (previously DEC2), a repressor of CLOCK/ARNTL activity, as a 
causal gene15,16, supporting the role of the circadian clock in sleep regulation. Previous 
genome-wide association studies (GWAS), including a recent GWAS in up to 128,286 
individuals, identified association of common variants at or near the PAX8 and VRK2 
genes, among other signals that have not yet been replicated13,14,17–19. 
 
Here, we extend GWAS of self-reported sleep duration in UK Biobank, test for 
consistency of effects in independent studies of adults and children/adolescents, 
determine their impact on accelerometer-derived estimates, perform pathway and tissue 
enrichment to highlight relevant biological processes and explore causal relationships 
with disease traits.   
 
Results 
GWAS for self-reported habitual sleep duration 
Among UK Biobank participants of European ancestry (n =446,118), mean self-reported 
habitual sleep duration was 7.2 hours (1.1 standard deviation) per day (Supplementary 
Table 1).  GWAS using 14,661,600 imputed genetic variants identified 78 loci (P < 5 x 10-
8; Figure 1a, Supplementary Data 1,2, Supplementary Figure 1a). Individual signals 
exert an average effect of 1.04 minutes (0.34 standard deviation) per allele, with the 
largest effect at the PAX8 locus, with an estimate of 2.44 minutes (0.16 standard error) 
per allele. The 5% of participants carrying the most sleep duration-increasing alleles self-
reported 22.2 minutes longer sleep duration compared to the 5% carrying the fewest. The 
78 loci explained 0.69% of the variance in sleep duration, and genome-wide SNP-based 
heritability was estimated at 9.8 (0.1)%. Of the 78 variants, 43 variants passed a more 
stringent multiple correction threshold of P < 6 x 10-9 established by permutation testing 
for a related sleep trait20. 
 Sensitivity analyses indicated that the 78 genetic associations were largely independent 
of known risk factors (Supplementary Data 3). Effect estimates at 15/78 loci were 
attenuated by 15-25% upon adjustment for frequent insomnia symptoms, perhaps 
reflecting contribution to an insomnia sub-phenotype with physiological hyperarousal and 
objective short sleep duration21 (Supplementary Data 3). Effect estimates at 19/78 were 
also slightly attenuated after adjustment of lifestyle factors. No signal attenuation was 
observed when accounting for BMI at rs9940646 at FTO, the established BMI-associated 
signal (r2 =0.81 with rs993960922 and where the higher BMI allele associated with shorter 
sleep duration). Analysis conditioned on the lead SNPs in each genomic region identified 
4 secondary association signals at the VRK2, DAT1 (SLC6A3), DRD2, and MAPT loci 
(Supplementary Table 2). Effect estimates were largely consistent in GWAS excluding 
shift workers and those with prevalent chronic and psychiatric disorders (excluding n 
=119,894 participants) (Supplementary Data 1,2, Supplementary Table 3, 
Supplementary Figure 1b,2). GWAS results were similar for men and women [rg (SE) 
=0.989 (0.042); P<0.001] (Supplementary Table 4, Supplementary Figure 1c,1d,3). 
 
GWAS for self-reported short and long sleep 
Separate GWAS for short (<7 hours; n =106,192 cases) and long (≥9 hours; n =34,184 
cases) sleep relative to 7-8 hours sleep duration (n=305,742 controls) highlighted 27 and 
8 loci, respectively, of which 13 were independent from the 78 sleep duration loci (Figure 
1b, Supplementary Data 2,4, Supplementary Table 5, Supplementary Figures 1e,1f). 
Only the PAX8 signal was shared across all 3 traits, consistently indicating associations 
between the minor allele and longer sleep duration. For most long sleep loci, we could 
exclude equivalent effects on short sleep based on 95% confidence intervals of effect 
estimates (Supplementary Figure 4, Supplementary Table 5). Sensitivity analyses 
accounting for factors potentially influencing sleep did not alter the results 
(Supplementary Data 5, Supplementary Table 6). 
Replication of sleep duration loci in independent studies 
We tested for independent replication of lead loci in the CHARGE consortium GWAS of 
adult sleep duration (n =47,180 from 18 studies14) and observed replication evidence for 
individual association signals at the PAX8, VRK2 and FBXL12/UBL5/PIN1 loci (P 
<6.4x10-4; Supplementary Data 2,6,7, Supplementary Figure 5a), with nominal 
replication (p<0.05) for 14 additional loci. Of the 70 loci covered in the CHARGE 
consortium, 55 signals showed a consistent direction of effect (binomial P =6.1x10-7), and 
a combined weighted genetic risk score (GRS) of the 70 signals was associated with a 
0.66 [95% CI: 0.54-0.78] minutes longer sleep per allele (P =1.23x10-25) in the CHARGE 
study (Table 1). Consistently strong genetic correlation was observed between the 
CHARGE and UK Biobank studies (rg (SE) =1.00 (0.123); P<0.001; Supplementary 
Table 7). In meta-analysis of UK Biobank and CHARGE consortium studies, 52/70 
signals retained GWAS significance, and 38/70 signals passed the more stringent 
multiple correction threshold of P<6x10-9 (Supplementary Data 6). 
 
In the childhood/adolescent GWAS for sleep duration from the EAGLE consortium19 (n 
=10,554), none of the 78 GWAS signals showed independent replication (all P >0.05; 
Supplementary Data 6,7, Supplementary Figure 5b). Of the 77 loci covered in the 
EAGLE consortium, marginal evidence of association was observed for the adult sleep 
duration loci, with 45/77 signals demonstrating consistent directionality (binomial P 
=0.031). For a combined 77 SNP GRS, we observed an effect of 0.16 [95% CI: 0.02-0.30] 
minutes longer sleep per allele (P =0.03; Table 1). No significant overall genetic 
correlation was observed with GWAS of adult sleep duration (rg (SE) =0.098 (0.076), P 
=0.20 with UK Biobank; Supplementary Table 7). In meta-analysis of all three sleep 
duration GWAS, 56/78 signals retained GWAS significance, and 40/78 passed the more 
stringent multiple correction threshold of P<6x10-9 (Supplementary Data 2,6,7, 
Supplementary Figure 5c). 
 
Association of sleep duration loci with objective sleep 
Given the limitations of self-reported sleep duration23,24, and in order to explore underlying 
physiologic mechanisms, in secondary analyses, we tested the 78 lead variants for 
association with 8 accelerometer-derived sleep estimates in a subgroup who had 
completed up to 7 days of wrist-worn accelerometry (n =85,499; Supplementary Table 
8)25. The lead PAX8 genetic variant was associated with 2.68 (0.29) minutes longer sleep 
duration (compared to 2.44 (0.16) minutes by self-report), 0.21 (0.04) % greater sleep 
efficiency, and 0.94 (0.23) minutes greater daytime inactivity duration per minor A allele 
(P <0.00064; Supplementary Data 8). The 5% of participants carrying the most sleep 
duration-increasing alleles were estimated to have 9.7 [95% CI: 7.5-11.8] minutes 
accelerometer measured longer sleep duration compared to the 5% carrying the fewest. 
The 78 SNP GRS associated with longer accelerometer-derived sleep duration, longer 
duration of daytime inactivity, greater sleep efficiency, and larger number of sleep bouts, 
but not with day-to-day variability in sleep duration or estimates of sleep timing (Table 1). 
A GRS of 27 short sleep variants was associated with shorter accelerometer-derived 
sleep duration, lower sleep efficiency and fewer sleep bouts, whereas a GRS of 8 long 
sleep variants associated with longer accelerometer-derived sleep duration, higher sleep 
efficiency, and longer daytime inactivity (Table 1, Supplementary Data 9).   
 
Functional annotation for identified loci 
The sleep duration association signals encompass >200 candidate causal genes 
determined by SNPsea26 through assessing linkage disequilibrium (LD) intervals of each 
identified loci, defined by the furthest SNPs in a 1 Mb window with r2 >0.05,  and a 
summary of reported gene-phenotype annotations is shown in Supplementary Data 10. 
Compelling candidates include genes in the dopaminergic (DRD2, SLC6A3), MAPK/ERK 
signaling (ERBB4, VRK2, KSR2), orexin receptor (HCRTR2) and GABA (GABRR1) 
signaling systems4,27. Further, studies of sleep regulation in animal models prioritize 
several candidates (GABRR1, GNAO1, HCRTR2, NOVA1, PITX3, SLC6A3 and DRD2, 
VAMP2 for sleep duration; PDE4B, SEMA3F for short sleep; PDE4D for long sleep). 
Circadian genes within associated loci include PER3, BTRC and the previously implicated 
PER128, which may act through glucocorticoid stress related pathways to influence sleep 
duration. Association signals at 4 loci directly overlapped with other GWAS signals (r2 
>0.8 in 1KG CEU; from NHGRI), with the shorter sleep allele associated with higher BMI 
(FTO), increased risk of Crohn’s disease (NFKB1, SLC39A8, BANK1 region), febrile 
seizures and generalized epilepsy (SCN1A), and cardiometabolic risk (FADS1/2 gene 
cluster), and decreased risk of interstitial lung disease (MAPT/KANSL). Fine-mapping 
using credible set analysis in PICS29 highlighted 52 variants (Supplementary Data 
11,12). Partitioning of heritability by functional annotations identified excess heritability 
across genomic regions conserved in mammals, consistent with earlier findings18, and 
additionally in regions with active promoters and enhancer chromatin marks 
(Supplementary Data 13). 
 
Gene and pathway based analysis 
Gene-based tests identified 235, 54 and 20 genes associated with sleep duration, short 
and long sleep, respectively (P ≤2.29x10-6; Supplementary Data 14,15). Pathway 
analyses of these genes using MAGMA30 and Pascal31 indicated enrichment of pathways 
including striatum and subpallium development, mechanosensory response, dopamine 
binding, catecholamine production, and long-term depression (Figure 2a,2b, 
Supplementary Table 9,10). In agreement with the FADS1/2 signal, we also observe 
enrichment in genes related to unsaturated fatty acid metabolism. A custom pathway 
analysis in Pascal indicated enrichment of association in a gene-set of synaptic sleep-
need-index phosphoproteins (SNIPPs), which have recently been demonstrated to be 
differentially phosphorylated based on sleep need in mouse models6 (Supplementary 
Table 11; Pemp=1.44x10-4). Of these, associations at SCN1A and PDE4B are genome-
wide significant.  
 
Tissue enrichment analyses of gene expression from GTEx tissues identified enrichment 
of associated genes in several brain regions including the cerebellum, a region of 
emerging importance in sleep/wake regulation32, frontal cortex, anterior cingulated cortex, 
nucleus accumbens, caudate nucleus, hippocampus, hypothalamus, putamen, and 
amygdala (Figure 2c, Supplementary Table 12). Enrichment was also observed in the 
pituitary gland. Single cell enrichment analyses in FUMA using a recently described 
Tabula Muris33 dataset showed enrichment in brain neurons and pancreatic alpha cells 
(Supplementary Data 16). Integration of gene expression data with GWAS using 
transcriptome-wide association analyses in 11 tissues34 identified 38 genes for which 
sleep duration SNPs influence gene expression in the tissues of interest (Supplementary 
Data 17).  
 
Several lead SNPs were associated with one or more of 3,144 human brain structure and 
function traits assessed in the UK Biobank (P <2.8x10-7, n =9,707; Oxford Brain Imaging 
Genetics Server35; Supplementary Figure 6). These include associations between the 
PAX8 locus with resting-state fMRI networks (Supplementary Figure 6a,6h,6m), 
rs13109404 (BANK1; Supplementary Figure 6b) and bilateral putamen and striatum 
volume, possibly relating to functional findings on reward processing after experimental 
sleep deprivation36, and rs330088 (PPP1R3B region; Supplementary Figure 6c) and 
temporal cortex morphometry, which may relate to recent findings showing extreme sleep 
durations predict subsequent frontotemporal gray matter atrophy37.  
 
Genetic correlation and Mendelian randomization 
Genome-wide genetic correlations using LD-score regression analyses38 indicated 
shared links between sleep duration and 8 cognitive, psychiatric and physical disease 
traits (Figure 3, Supplementary Data 18). We observed modest positive genetic 
correlations between sleep duration and schizophrenia, bipolar disorder, and age at 
menarche, and a negative correlation with insomnia that persisted even upon excluding 
participants with psychiatric disorders, indicating that genetic relationships are not driven 
by the presence of co-morbid conditions. In addition, both short and long sleep showed 
positive genetic correlations with depressive symptoms, waist circumference, waist-to-hip 
ratio and negative correlations with years of schooling. For short sleep, genetic 
correlations were also observed with insomnia, neuroticism, and smoking, and for long 
sleep, positive correlations were evident with schizophrenia, body fat, type 2 diabetes, 
and coronary artery disease.  
 
Mendelian Randomization (MR) analyses to test for causal links between sleep duration 
and genetically correlated traits suggested longer sleep duration is causal for increased 
risk of schizophrenia [two-sample MR: inverse variance weighted: 0.0088 (0.003) log 
odds ratio per minute, P =3.70 x 10-3; weighted median: 0.008 (0.003) log odds ratio per 
minute, P =3.95 x 10-3] (Figure 4, Supplementary Table 13). These data suggest that a 
one-hour longer sleep duration leads to a 69.6% increase risk for schizophrenia. In leave-
one-out sensitivity analyses, MR results remained robust and consistent (all P <6.86 x 10-
3; Supplementary Data 19). Sensitivity MR analyses limited to signals from GWAS 
adjusting for confounders (BMI, insomnia, or other lifestyle traits) and using 
corresponding effect estimates remained significant (Supplementary Table 14). In 
addition, MR remained significant when restricted to the 56 signals that retained GWAS 
significance in meta-analysis (Supplementary Table 14). Conversely, MR also indicated 
that risk of schizophrenia is causal for longer sleep duration [inverse variance weighted: 
0.025 (0.007) minutes per log odds ratio, P =6.05 x 10-4; two-sample MR: weighted 
median: 0.026 (0.006) minutes per log odds ratio, P =3.36 x 10-5] (Figure 4, 
Supplementary Table 14). These data suggest a 1.04 hour longer sleep duration per 
doubling in risk of schizophrenia. No other causal links were identified in two-sample MR. 
Furthermore, using two sample MR with data from the GIANT consortium39 (n = 339,224) 
and DIAGRAM consortium40 (n =26,488 cases and n =83,964 controls) we found no 
evidence of causal effects of altered sleep duration with BMI and type 2 diabetes 
(Supplementary Table 13, Supplementary Figure 7). 
 
 
Discussion 
This study expands our understanding of the genetic architecture of self-reported sleep 
duration, estimating SNP-based heritability at 9.8%, consistent with earlier reports41. We 
identified 76 independent loci beyond the two previously known loci (PAX8 and 
VRK214,17,18). The largest effect remains at the PAX8 locus (2.44 minutes per allele), 
consistent with previous reports14,17,18. Whereas individual signals exerted more modest 
effects on average (~1.04 minutes per allele), the aggregate effect of risk alleles could 
exceed 20 minutes, which is comparable to other well-recognized factors influencing 
sleep duration, such as gender42. Our GWAS findings were largely consistent upon 
adjustment for known risk factors, including BMI, however attenuated effects were seen 
for some loci with adjustment for insomnia, reflecting some overlap between these sleep 
characteristics.  
 
In separate GWAS for short and long sleep duration, 13 additional independent variants 
were identified, and only the PAX8 locus was shared across all 3 GWASs. Our distinct 
findings for short and long sleep suggest the possibility of some distinct underlying 
biological mechanisms. As all 3 sleep traits were correlated, however, we did not account 
for multiple testing as have been done in previous GWAS of multiple correlated traits18. 
Future larger studies will be necessary to test if these loci reflect partially distinct genetic 
effects on short or long sleep, or reflect differences in statistical power in these 
dichotomized analyses. 
 
The CHARGE consortium (adults) and EAGLE consortium (children/adolescents) sleep 
duration GWAS studies represent the largest independent available studies for 
replication, but are considerably smaller than the UK Biobank discovery cohort which 
limits opportunities for adequate replication43. Indeed, we had limited power to replicate 
individual SNPs in the two replication cohorts: The CHARGE consortium study with 
~1/10th the sample size of the UK Biobank provided <12.5% power for all SNPs that did 
not individually replicate, and the EAGLE consortium study with ~1/40th the sample size 
of the UK Biobank provided power <70% for all SNPs that did not individually replicate. 
Despite these limitations, 52 loci remained significant after meta-analysis of both adult 
studies and 56 loci remain significant after meta-analysis of all three studies, a substantial 
advance over knowledge from prior studies. Future replication is necessary when 
appropriate resources become available, such as the US Department of Veterans Affairs 
Million Veteran Program and the All of Us Research program. 
 
Furthermore, we validated effects of the combined sleep duration GRS in both adults and 
in children/adolescents, further supporting our findings. Consistency between findings 
from the UK Biobank GWAS and sleep duration in independent studies despite 
differences in demographics and sleep duration ascertainment, two important extraneous 
factors that may influence self-report44, reflect the generalizability of our signals. However, 
smaller effect estimates of the GRS in children/adolescents compared to adults supports 
previous studies that suggest the genetic architecture of sleep duration might differ 
between children and adults19. Furthermore, our finding of no significant overall genetic 
correlation between the GWAS of adults and children/adolescents sleep duration, as 
reported previously19, supports changes in sleep patterns throughout the lifespan45–47, 
and larger GWAS of sleep duration in children/adolescents are needed.  
 
Despite limitations of biases and imprecision in self-report, we observed largely consistent 
effects of our 78 signals with accelerometer-estimated sleep duration in a large 
subsample of 85,499 participants from the UK Biobank with up to 7 days of wrist-worn 
accelerometer. Self-report, actigraphy and polysomnography estimated sleep duration 
provide both unique and overlapping information, have different sources of measurement 
error and may reflect different neurophysiological and psychological aspects23,24,44. 
Association of the sleep duration GRS with increased sleep efficiency, longer duration of 
daytime inactivity, but a larger number of sleep bouts, suggests that sleep duration 
genetic loci might impact other correlated parameters such as sleep latency, sleep 
fragmentation and early awakening. Therefore, this secondary analysis allows us to begin 
exploring physiologic mechanisms underlying these associations. However, considering 
that the UK Biobank subsample with accelerometer data overlaps with the discovery 
GWAS sample, these results should be interpreted with caution and further validation in 
an independent dataset is necessary. Furthermore, our study cannot resolve if a longer 
sleep GRS always reflects improved, higher quality sleep because of increased sleep 
efficiency, or may include qualitatively poorer, longer sleep or greater sleep need, given 
association with a larger number of sleep bouts and increased daytime napping. Thus, 
further investigation of the role of these loci in EEG-derived physiological correlates of 
sleep architecture and sleep homeostasis from polysomnography, and follow-up in 
cellular and animal models will help to dissect functional mechanisms.  
 
We found compelling evidence of association near genes implicated with sleep traits in 
animal models, confirming that sleep-wake regulation is a highly conserved process with 
mechanisms shared between humans and model organisms. In agreement with the 
FADS1/2 signal, we also observe an enrichment in genes related to unsaturated fatty acid 
metabolism, supporting experimental and observational evidence linking polyunsaturated 
fatty acids with sleep and related diseases, including neuropsychiatric disorders and 
depression48–50. We demonstrate enrichment in sleep duration GWAS signals within/near 
80 genes identified as SNIPPs in mouse models6, highlighting the potential importance 
of synaptic phosphorylation in sleep homeostasis in humans. A genetic variant, 
rs9382445, near the orexin receptor HCRTR2 previously implicated for chronotype17 
associated significantly with sleep duration and retained significance and consistent effect 
estimates upon adjustment for diurnal preference.  
 
Lastly, we extended the comparative analysis of the genetic architecture of sleep duration 
with other traits and found shared links between continuous sleep duration and cognitive, 
psychiatric and disease traits, as well as u-shaped genetic correlations between short 
and long sleep duration and key lifestyle and disease traits including adiposity traits, years 
of schooling and depressive symptoms. In bidirectional two-sample MR analyses, we 
observed causal links between longer sleep duration and increased risk of schizophrenia, 
consistent with previous findings18,51, and conversely, causal links between schizophrenia 
and longer sleep duration. Associations remained robust in sensitivity analyses and the 
bidirectional causal link may suggest pleiotropy. Furthermore, MR effects may be biased 
due to collider bias as individuals with a genetic liability to neuropsychiatric diseases are 
underrepresented in studies such as the UK Biobank compared to the general population, 
whilst some independent protective factors for these conditions, including favorable sleep 
patterns, may be over-represented52,53. No other causal links were identified. Considering 
the non-specific and partially overlapping signals between the sleep duration and 
short/long sleep GWAS, we limited our MR analyses to sleep duration, and future MR 
should be carried out for short/long sleep duration separately. Follow-up MR analyses are 
warranted to verify null results identified in the one-sample insomnia MR, as well as other 
outcomes beyond those investigated. 
 
In summary, our GWAS constitutes a large increase in associated loci for sleep duration 
that implicate multiple biological pathways and causal links to disease. This work and 
follow-up studies will advance understanding of the molecular processes underlying sleep 
regulation and have the potential to identify new avenues of treatment for sleep and 
related disorders. 
 
Methods: 
Population and study design 
Study participants were from the UK Biobank study, described in detail elsewhere54. In 
brief, the UK Biobank is a prospective study of >500,000 people living in the United 
Kingdom. All people in the National Health Service registry who were aged 40-69 and 
living <25 miles from a study center were invited to participate between 2006-2010. In 
total 503,325 participants were recruited from over 9.2 million invitations. Extensive 
phenotypic data were self-reported upon baseline assessment by participants using 
touchscreen tests and questionnaires and at nurse-led interviews. Anthropometric 
assessments were also conducted and health records were obtained from secondary 
care data from linked Hospital episode statistics (HES) obtained up until 04/2017. For the 
current analysis, 24,533 individuals of non-white ethnicity (as defined in Genotyping and 
quality control) were excluded to avoid confounding effects. The UK Biobank study was 
approved by the National Health Service National Research Ethics Service (ref. 
11/NW/0382), and all participants provided written informed consent to participate in the 
UK Biobank study. 
 
Sleep duration and covariate measures 
Study participants (n ~500,000) self-reported sleep duration at baseline assessment. 
Participants were asked, About how many hours sleep do you get in every 24 hours? 
(please include naps), with responses in hour increments. Sleep duration was treated as 
a continuous variable and also categorized as either short (6 hours or less), normal (7 or 
8 hours), or long (9 hours or more) sleep duration. Extreme responses of less than 3 
hours or more than 18 hours were excluded17 and Do not know or Prefer not to answer 
responses were set to missing. Participants who self-reported any sleep medication (see 
Supplementary Method 1) were excluded. Furthermore, participants who self-reported 
any shift work or night shift work or those with prevalent chronic disease (i.e., breast, 
prostate, bowel or lung cancer, heart disease or stroke) or psychiatric disorders (see 
Supplementary Method 2) were later additionally excluded in a secondary GWAS. 
 
Participants further self-reported age, sex, caffeine intake (self-reported cups of tea per 
day and cups of coffee per day), daytime napping (Do you have a nap during the day?), 
smoking status, alcohol intake frequency (never, once/week, 2-3 times/week, 4-6 
times/week, daily), chronotype (Do you consider yourself to be …, with the following 
response options: Definitely a 'morning' person, More a 'morning' than 'evening' person, 
More an 'evening' than a 'morning' person, and Definitely an 'evening' person,), 
menopause status, and employment status during assessment. Socio-economic status 
was represented by the Townsend deprivation index based on national census data 
immediately preceding participation in the UK Biobank. Weight and height were measured 
and body-mass index (BMI) was calculated as weight (kg) / height2(m2). Cases of sleep 
apnea were determined from self-report during nurse-led interviews or health records 
using International Classification of Diseases (ICD)-10 codes for sleep apnea (G47.3). 
Cases of insomnia were determined from self-report to the question, Do you have trouble 
falling asleep at night or do you wake up in the middle of the night? with responses 
never/rarely, sometimes, usually, prefer not to answer. Participants who responded 
usually were set as insomnia cases, and remaining participants were set as controls. 
Missing covariates were imputed by using sex-specific median values for continuous 
variables (i.e., BMI, caffeine intake, alcohol intake, and Townsend index), or using a 
missing indicator approach for categorical variables (i.e., napping, smoking, menopause, 
employment, and chronotype). 
 
Activity-monitor derived measures of sleep 
Actigraphy devices (Axivity AX3) were worn 2.8 - 9.7 years after study baseline by 
103,711 individuals from the UK Biobank for up to 7 days55. Of these 103,711 individuals, 
we excluded 11,067 individuals based on accelerometer data quality. Samples were 
excluded if they satisfied at least one of the following conditions (see also 
http://biobank.ctsu.ox.ac.uk/crystal/label.cgi?id=1008): a non-zero or missing value in 
data field 90002 (Data problem indicator), good wear time flag (field 90015) set to 0 (No), 
good calibration flag (field 90016) set to 0 (No), calibrated on own data flag (field 90017) 
set to 0 (No) or overall wear duration (field 90051) less than 5 days. Additionally, samples 
with extreme values of mean sleep duration (<3 hours or >12 hours) or mean number of 
sleep periods (<5 or >30) were excluded. 85,502 samples remained after non-white 
ethnicity exclusions. Sleep measures were derived by processing raw accelerometer data 
(.cwa). First we converted .cwa files available from the UK Biobank to .wav files using 
Omconvert 
(https://github.com/digitalinteraction/openmovement/tree/master/Software/AX3/omconve
rt ) for signal calibration to gravitational acceleration55,56 and interpolation55. The .wav files 
were processed with the R package GGIR to infer activity monitor wear time57, and extract 
the z-angle across 5-second epoch time-series data for subsequent use in estimating the 
sleep period time window (SPT-window)25 and sleep episodes within it58. 
 
The SPT-window was estimated using an algorithm25 implemented in the GGIR R 
package and validated using PSG in an external cohort consisting of 28 adult sleep clinic 
patients and 22 healthy good sleepers. Briefly, for each individual, median values of the 
absolute change in z-angle (representing the dorsal-ventral direction when the wrist is in 
the anatomical position) across 5-minute rolling windows were calculated across a 24-
hour period, chosen to make the algorithm insensitive to activity-monitor orientation. The 
10th percentile was incorporated into the threshold distinguishing movement from non-
movement. Bouts of inactivity lasting ≥30 minutes are recorded as inactivity bouts. 
Inactivity bouts that are <60 minutes apart are combined to form inactivity blocks. The 
start and end of longest block defines the start and end of the SPT-window25. Sleep 
duration. Sleep episodes within the SPT-window were defined as periods of at least 5 
minutes with no change larger than 5° associated with the z-axis of the accelerometer58. 
The summed duration of all sleep episodes was used as indicator of sleep duration. Sleep 
efficiency. This was calculated as sleep duration (defined above) divided by the time 
elapsed between the start of the first inactivity bout and the end of the last inactivity bout 
(which equals the SPT-window duration). Number of sleep bouts within the SPT-window. 
This is defined as the number of sleep bouts separated by last least 5 minutes of 
wakefulness within the SPT-window. The least-active five hours (L5) and the most-active 
ten hours (M10) of each day were defined using a five-hour and ten-hour daily period of 
minimum and maximum activity, respectively. These periods were estimated using a 
rolling average of the respectively time window. L5 was defined as the number of hours 
elapsed from the previous midnight whereas M10 was defined as the number of hours 
elapsed from the previous midday. Sleep midpoint was calculated for each sleep period 
as the midpoint between the start of the first detected sleep episode and the end of the 
last sleep episode used to define the overall SPT-window (above). This variable is 
represented as the number of hours from the previous midnight, e.g. 2am = 26. Daytime 
inactivity duration is the total daily duration of estimated bouts of inactivity that fall outside 
of the SPT-window. A minimum of 16 wear-hours was required for each night to be 
included. For non-wear data, the sleep phenotypes were imputed. Briefly, a minimum of 
16 wear-hours was required for each night to be included. For each 15-minute block that 
was classified as non-wear, data were replaced by the average of blocks at the same 
time periods from the other days in each individual record57. All activity-monitor 
phenotypes were adjusted for age at accelerometer wear, sex, season of wear, release 
(categorical; UK BiLeVe, UK Biobank Axiom interim, release UK Biobank Axiom full 
release) and number of valid recorded nights (or days for M10) when performing the 
association test in BOLT-LMM. Genetic risk scores for sleep duration, short sleep and 
long sleep were tested using the weighted genetic risk score calculated by summing the 
products of the sleep trait risk allele count for all 78, 27, or 8 genome-wide significant 
SNPs multiplied by the scaled effect from the primary GWAS using the GTX package in 
R. 
 
Genotyping and quality control 
Phenotype data is available for 502,631 subjects in the UK Biobank. Genotyping was 
performed by the UK Biobank, and genotyping, quality control, and imputation procedures 
are described in detail here59. In brief, the following was conducted by the UK Biobank. 
Blood, saliva, and urine was collected from participants, and DNA was extracted from the 
buffy coat samples. Participant DNA was genotyped on two arrays, UK BiLEVE and UK 
Biobank Axiom with >95% common content and genotypes for ~800,000 autosomal SNPs 
were imputed to two reference panels. Genotypes were called using Affymetrix Power 
Tools software. Sample and SNPs for quality control were selected from a set of 489,212 
samples across 812,428 unique markers. Sample QC was conducted using 605,876 high 
quality autosomal markers. Samples were removed for high missingness or 
heterozygosity (968 samples) and sex chromosome abnormalities (652 samples). 
Genotypes for 488,377 samples passed sample QC (~99.9% of total samples). Marker 
based QC measures were tested in the European ancestry subset (n=463,844), which 
was identified based on principal components of ancestry. SNPs were tested for batch 
effects (197 SNPs/batch), plate effects (284 SNPs/batch), Hardy-Weinberg equilibrium 
(572 SNPs/batch), sex effects (45 SNPs/batch), array effects (5417 SNPs), and 
discordance across control replicates (622 on UK BiLEVE Axiom array and 632 UK 
Biobank Axiom array) (p-value <10-12 or <95% for all tests). For each batch (106 batches 
total) markers that failed at least one test were set to missing. Before imputation, 805,426 
SNPs pass QC in at least one batch (>99% of the array content). Population structure 
was captured by principal component analysis on the samples using a subset of high 
quality (missingness <1.5%), high frequency SNPs (>2.5%) (~100,000 SNPs) and 
identified the sub-sample of white British descent. In addition to the calculated population 
structure by the UK Biobank, we locally further clustered subjects into four ancestry 
clusters using K-means clustering on the principal components, identifying 453,964 
subjects of European ancestry. The UK Biobank centrally further imputed autosomal 
SNPs to UK10K haplotype, 1000 Genomes Phase 3, and Haplotype Reference 
Consortium (HRC) with the current analysis using only those SNPs imputed to the HRC 
reference panel. Autosomal SNPs were pre-phased using SHAPEIT3 and imputed using 
IMPUTE4. In total ~96 million SNPs were imputed. Related individuals were identified by 
estimating kinship coefficients for all pairs of samples, using only markers weakly 
informative of ancestral background. In total, there are 107,162 related pairs comprised 
of 147,731 individuals related to at least one other participants in the UK Biobank. 
 
Genome-wide association analysis 
Genetic association analysis was performed in related subjects of European ancestry (n 
=446,118) using BOLT-LMM60 linear mixed models and an additive genetic model 
adjusted for age, sex, 10 principal components of ancestry, genotyping array and genetic 
correlation matrix [jl2] with a maximum per SNP missingness of 10% and per sample 
missingness of 40%. We used a genome-wide significance threshold of 5x10-8 for each 
GWAS. OR [95% CI] estimates for short/long sleep are from adjusted PLINK61 logistic 
regression analyses where genetic association analysis was also performed in unrelated 
subjects of white British ancestry (n =326,224) using PLINK logistic regression and an 
additive genetic model adjusted for age, sex, 10 PCs and genotyping array to determine 
SNP effects on sleep traits. We used a hard-call genotype threshold of 0.1, SNP 
imputation quality threshold of 0.80, and a MAF threshold of 0.001. Genetic association 
analysis for the X chromosome was performed using the genotyped markers on the X 
chromosome with the additional –sex flag in PLINK. Similarly, sex-specific GWAS were 
also performed using BOLT-LMM60 linear mixed models. Trait heritability was calculated 
as the proportion of trait variance due to additive genetic factors measured in this study 
using BOLT-REML60, to leverage the power of raw genotype data together with low 
frequency variants (MAF≥0.001). Lambda inflation (λ) values were calculated using 
GenABEL in R, and estimated values were consistent with those estimated for other 
highly polygenic complex traits. Additional independent risk loci were identified using the 
approximate conditional and joint association method implemented in GCTA (GCTA-
COJO)62. 
 
Sensitivity analyses of top signals 
Follow-up analyses on genome-wide significant loci in the primary analyses included 
covariate sensitivity analyses adjusting for BMI, insomnia (continuous only), chronotype 
(continuous only), or caffeine intake adjustments individually, or a combined adjustment 
for lifestyle and clinical traits, including day naps, Townsend index, smoking, alcohol 
intake, menopause status, employment status, and sleep apnea in addition to baseline 
adjustments for age, sex, 10 principal components of ancestry, and genotyping array. 
Sensitivity analyses were performed using BOLT-LMM60 linear mixed models using the 
same input set of SNPS (i.e., hard-call genotypes) as for the main GWAS, and OR [95% 
CI] estimates for short/long sleep are from adjusted PLINK61 logistic regression analyses 
in unrelated subjects of white British ancestry.  
 
Replication and meta-analyses of sleep duration loci 
Using publicly available databases, we conducted a lookup of lead self-reported sleep 
duration signals in self-reported sleep duration GWAS results from adult (CHARGE; n 
=47,180) and childhood/adolescent (EAGLE; n =10,554). If lead signal was unavailable, 
a proxy SNP was used instead. As different imputation panels were used compared to 
the UK Biobank, 8 of the 78 SNPs and 1 of the 78 SNPs were not covered in the CHARGE 
consortium and EAGLE consortium, respectively. In addition, we combined self-reported 
sleep duration GWAS results from adult (CHARGE) and childhood/adolescent (EAGLE) 
with the UK Biobank (primary model) in fixed-effects meta-analyses using the inverse 
variance-weighted method in METAL63. Meta-analyses were conducted first separately 
[UK Biobank + CHARGE (n=3,044,490 variants) or UK Biobank + EAGLE (n=7,147,509 
variants)], then combined (UK Biobank + CHARGE + EAGLE; n=2,545,157 variants). A 
genetic risk score for sleep duration was tested using the weighted genetic risk score 
calculated by summing the products of the sleep duration risk allele count for as many 
available SNPs of the 78 genome-wide significant SNPs in each study (70 for CHARGE, 
77 for EAGLE) multiplied by the scaled effect from the primary GWAS using the GTX 
package in R64. 
 
 
 
Gene, pathway and tissue-enrichment analyses 
Genes overlapping the linkage disequilibrium (LD) interval of the identified loci, defined 
by the furthest SNPs in a 1 Mb window with r2 >0.05, were identified by SNPsea26. Gene-
based analysis was performed using Pascal31. Pascal gene-set enrichment analysis uses 
1,077 pathways from KEGG, REACTOME, BIOCARTA databases, and a significance 
threshold was set after Bonferroni correction accounting for 1,077 pathways tested (P 
<0.05/1,077). Pathway analysis was also conducted using MAGMA30 gene-set analysis 
in FUMA65, which uses the full distribution of SNP P values and is performed for curated 
gene sets and GO terms obtained from MsigDB (total of 10,891 pathways). A significance 
threshold was set after Bonferroni correction accounting for all pathways tested 
(P <0.05/10,891). Using PASCAL, we created a custom pathway of the synaptic sleep-
need-index phosphoproteins (SNIPPs) genes6 using human orthologs identified in DAVID 
(79 out of 80 identified SNIPPs). We then verified enrichment of the in our sleep duration 
GWAS (continuous, short, and long sleep). Tissue enrichment analysis was conducted 
using FUMA65 for 53 tissue types, and a significance threshold was set following 
Bonferroni correction accounting for all tested tissues (P <0.05/53). Single cell enrichment 
analysis was conducted in FUMA65 utilizing the Tabula Muris33 dataset, and a significance 
threshold was set following Bonferroni correction accounting for all tested cell types 
(P <0.05/115). Integration of gene expression data with GWAS using transcriptome-wide 
association analyses in 11 tissues34 identified 38 genes for which sleep duration SNPs 
influence gene expression in the tissues of interest (Supplementary Table 28). 
Integrative transcriptome-wide association analyses with GWAS were performed using 
the FUSION TWAS package34 with weights generated from gene expression in 9 brain 
regions and 2 tissues from the GTEx consortium (v6). Tissues for TWAS testing were 
selected from the FUMA tissue enrichment analyses and here we present significant 
results that survive Bonferroni correction for the number of genes tested per tissue and 
for all 11 tissues.  
 
 
Genetic correlation analyses 
Post-GWAS genome-wide genetic correlation analysis of LD Score Regression 
(LDSC)66–68 using LDHub was conducted using all UK Biobank SNPs also found in 
HapMap3 and included publicly available data from 224 published genome-wide 
association studies, with a significance threshold after Bonferroni correction for all tests 
performed (P  <0.05/224 tests). LDSC estimates genetic correlation between two traits 
from summary statistics (ranging from -1 to 1) using the fact that the GWAS effect-size 
estimate for each SNP incorporates effects of all SNPs in LD with that SNP, SNPs with 
high LD have higher X2 statistics than SNPs with low LD, and a similar relationship is 
observed when single study test statistics are replaced with the product of z-scores from 
two studies of traits with some correlation.  Furthermore, genetic correlation is possible 
between case/control studies and quantitative traits, as well as within these trait types. 
We performed partitioning of heritability using the 8 pre-computed cell-type regions, and 
25 pre-computed functional annotations available through LDSC, which were curated 
from large-scale robust datasets66. Enrichment both in the functional regions and in an 
expanded region (+500bp) around each functional class was calculated in order to 
prevent the estimates from being biased upward by enrichment in nearby regions. The 
multiple testing threshold for the partitioning of heritability was determined using the 
conservative Bonferroni correction (P <0.05/25 classes). Summary GWAS statistics will 
be made available at the UK Biobank web portal.  
 
Mendelian Randomization analyses 
MR analysis was carried out using the R package MR-Base69 (available: 
github.com/MRCIEU/TwoSampleMR), using the inverse variance weighted approach as 
our main analysis method70, and MR-Egger71 and weighted median estimation72 as 
sensitivity analyses. MR results may be biased by horizontal pleiotropy – i.e. where the 
genetic variants that are robustly related to the exposure of interest (here sleep duration) 
independently influence levels of a causal risk factor for the outcome. IVW assumes that 
there is either no horizontal pleiotropy, or that, across all SNPs, horizontal pleiotropy is (i) 
uncorrelated with SNP-risk factor associations and (ii) has an average value of zero. MR-
Egger assumes (i) but relaxes (ii) by explicitly estimating the non-zero mean pleiotropy, 
and adjusting the causal estimate accordingly. Estimation of the pleiotropy parameter 
means that the MR-Egger estimate is generally far less precise than the IVW estimate. 
The weighted median approach is valid if less than 50% of the weight is pleiotropic (i.e. 
no single SNP that contributes 50% of the weight or a number of SNPs that together 
contribute 50% should be invalid because of horizontal pleiotropy). Given these different 
assumptions, if all three methods are broadly consistent this strengthens our causal 
inference. For all our MR analyses, except insomnia, we used two-sample MR, in which, 
for all 78 GWAS hits identified in this study for sleep duration, we looked for the per allele 
difference in odds (binary outcomes) or means (continuous) with outcomes from summary 
publicly available data in the MR-Base platform. Results are therefore a measure of 
‘longer sleep duration’ and sample 1 is UK Biobank (our GWAS) and sample 2 a number 
of different GWAS consortia covering the outcomes we explored. For interpretation 
purposes, inverse variance weighted MR causal effect estimates were converted in OR 
per hour by multiplying log ORs by 60 in order to represent the OR per hour, and then 
exponentiating. For significant two-sample MR findings, in sensitivity analyses, we further 
conducted leave-one-out analyses, MR using sleep duration effect estimates adjusting 
for standard confounders including BMI, insomnia, and other lifestyle factors, and 
restricted to those GWAS variants from each respective analysis, MR restricted to the 
signals that retained GWAS significance in meta-analysis, and lastly, reverse direction 
MR analysis. For reverse direction MR, inverse variance weighted MR causal effect 
estimates in minutes were first converted to hours by multiplying by 60, and then were 
converted by multiplying by 0.693 (=ln(2)) in order to represent changes in sleep duration 
in hours per doubling in odds of the binary exposure. The number of SNPs used in each 
MR analysis varies by outcome from because of some SNPs (or proxies for them) not 
being located in the outcome GWAS. In addition, for schizophrenia MR, we excluded two 
pleiotropic SNPs rs34556183 (near HIST1H2BJ) and rs13109404 (near SLC39A8) from 
our analysis, and to test for bidirectional links, we derived the schizophrenia instrumental 
variable using GWAS variants reported by the Psychiatric Genomics Consortium 
Schizophrenia working group73. 
 
Data Availability 
Summary GWAS statistics are publicly available at the Sleep Disorder Knowledge Portal 
(http://sleepdisordergenetics.org/) and the UK Biobank website 
(http://biobank.ctsu.ox.ac.uk/). 
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Figures 
 
Figure 1. Plots for genome-wide association analysis results for sleep duration and 
short/long sleep.  
 
a) Manhattan plot of sleep duration (n =446,118), and b) Miami plot of short (cases n 
=106,192/305,742) and long (cases n =34,184/305,742) sleep. Plots show the -log10 P 
values (y-axis) for all genotyped and imputed SNPs passing quality control in each 
GWAS, plotted by chromosome (x-axis). Blue peaks represent genome-wide significant 
loci. Horizontal red line denotes genome-wide significance (P =5 x 10-8). 
 
Figure 2. Pathway-based and tissue expression enrichment analyses for sleep 
duration.  
 
a) Pathway analysis is based on MAGMA gene-sets. Top 10 of 10,891 pathways are 
shown, and significant pathways are indicated in orange (P <4.59 x 10-6). For each 
significant pathway, respective sleep genes are indicated with a colored orange box. 
Sleep genes from significant pathways that overlap with remaining pathways are 
indicated in blue. b) Pathway analysis is based on Pascal (gene-set enrichment analysis 
using 1,077 pathways from KEGG, REACTOME, BIOCARTA databases) Top 10 
pathways are shown, and significant pathways are indicated in orange (P <4.64 x 10-5). 
c) MAGMA tissue expression analysis using gene expression per tissue based on GTEx 
RNA-seq data for 53 specific tissue types. Significant tissues are shown in red (P <9.43 
x 10-4). All pathway and tissue expression analyses in this figure can be found in tabular 
form in Supplementary Tables 9,10,12. 
 
Figure 3. Shared genetic architecture between sleep duration and behavioral and 
disease traits.  
 
LD score regression estimates of genetic correlation (rg) were obtained by comparing 
genome-wide association estimates for sleep duration with summary statistics estimates 
from 224 publically available GWAS. Blue, positive genetic correlation; red, negative 
genetic correlation; rg values are displayed for significant correlations. Larger colored 
squares correspond to more significant P values, and asterisks indicate significant (P <2.2 
x 10-4) genetic correlations. All genetic correlations in this report can be found in tabular 
form in Supplementary Data 18. 
 
 
 
 
 
 
 
Figure 4. Bidirectional causal relationship of sleep duration with schizophrenia using 
Mendelian Randomization.  
 
Association between single nucleotide polymorphisms (SNP) associated with sleep 
duration and schizophrenia (a) or SNP associated with schizophrenia and sleep duration 
(c) and forest plots show the estimate of the effect of genetically increased sleep duration 
on schizophrenia (b) or increased risk of schizophrenia on sleep duration (d). Lines 
identify the slopes for three Mendelian Randomization (MR) association tests (a,c). Forest 
plots show each SNP with the 95% confidence interval (gray line segment; error bars) of 
the estimate and the Inverse Variance MR, MR-Egger, and Weighted Median MR results 
in red. 
Table 1. A risk score of genetic variants for self-reported sleep duration (78 SNPs), self-reported short 
(27 SNPs) or long (8 SNPs) sleep duration associates with self-reported sleep duration in the 
CHARGE (adult) consortium (n =47,180), self-reported sleep duration in the EAGLE 
(childhood/adolescent) consortium (n =10,554), and activity-monitor based measures of sleep 
fragmentation, timing and duration from 7 day accelerometry in the UK Biobank (n =85,499). 
  
 Sleep Duration GRS Short Sleep GRS Long Sleep GRS 
Trait 
Beta or OR* 
[95% CI] per 
effect allele P value 
Beta or OR* 
[95% CI] per 
effect allele P value 
Beta or OR* 
[95% CI] per 
effect allele P value 
CHARGE Study (n =47,180)  
Self-reported sleep duration (minutes)# 
0.66 [0.54 – 
0.78] 
1.23 x 
10-25 
    
EAGLE Study (n =10,554)  
Self-reported sleep duration (minutes) † 
0.16 [0.02 – 
0.30] 
2.80 x 
10-2 
    
       
UK Biobank 7-day Accelerometry  
(n =85,499)  
Sleep Duration Estimates 
      
Sleep duration (minutes) 
0.47 [0.40 – 
0.53] 
1.93 x 
10-44 
-0.43 [-0.56 
– -0.31] 
1.21 x 
10-11 
2.12 [1.65 – 
2.59] 
1.08 x 
10-18 
Short sleep duration  
(n=13,760 cases, 66,110 controls) 
0.98 [0.98 – 
0.99]* 
4.00 x 
10-19 
1.02 [1.01 –
1.02]* 
4.91 x 
10-6 
0.94 [0.92 – 
0.97]* 
1.10 x 
10-5 
Long sleep duration  
(n=5,629 cases, 66,110 controls) 
1.01 [1.01 – 
1.02]* 
3.78 x 
10-9 
0.99 [0.98 – 
1.00]* 
0.11 
1.10 [1.07 – 
1.14]* 
1.29 x 
10-8 
Daytime Inactivity Duration (minutes) 
0.08 [0.03 – 
0.13] 
2.74 x 
10-3 
0.01 [-0.09 – 
0.11] 
0.89 
0.65 [0.28 – 
1.02] 
6.49 x 
10-4 
Sleep duration standard deviation 
(minutes) 
-0.02 [-0.07 – 
0.02] 
0.34 
0.05 [-0.04 – 
0.14] 
0.26 
-0.07 [-0.40 – 
0.27] 
0.69 
Sleep Fragmentation Estimates       
Sleep efficiency % 
0.05 [0.04 – 
0.06] 
8.38 x 
10-23 
-0.05 [-0.07 
– -0.04] 
4.79 x 
10-9 
0.15 [0.08 – 
0.22] 
1.56 x 
10-5 
Number of sleep bouts (n) 
0.02 [0.01 – 
0.02] 
1.59 x 
10-10 
-0.01 [-0.02 
– 0.00] 
2.42 x 
10-3 
0.02 [-0.01 – 
0.05] 
0.24 
Sleep Timing Estimates       
Midpoint of 5-hour daily period of 
minimum activity (L5 timing) (minutes) 
-0.05 [-0.13 – 
0.03] 
0.23 
0.07 [-0.09 – 
0.22] 
0.41 
0.39 [-0.20 – 
0.97] 
0.20 
Midpoint of 10-hour daily period of 
maximum activity (M10 timing) (minutes) 
0.03 [-0.06 – 
0.12] 
0.51 
-0.05 [-0.23 – 
0.12] 
0.55 
0.65 [-0.02 – 
1.32] 
6.00 x 
10-2 
Sleep Midpoint (minutes) 
-0.03 [-0.07 – 
0.01] 
0.20 
0.01 [-0.07 – 
0.08] 
0.88 
0.05 [-0.24 – 
0.34] 
0.74 
 
Genetic risk scores for sleep duration, short sleep and long sleep were tested using the weighted genetic risk score calculated 
by summing the products of the sleep trait risk allele count for all 78, 27, or 8 genome-wide significant SNPs multiplied by the 
scaled effect from the primary GWAS using the GTX package in R. Effect estimates (Beta or OR) are reported per each additional 
effect allele for sleep duration, short sleep, or long sleep. Abbreviations: CI=confidence interval, GRS=genetic risk score, 
OR=odds ratio. 
# Self-reported and varied by cohorts, typically: “How many hours of sleep do you usually get at night (or your main sleep period)?" 
† In all cohorts, except in GLAKU, child sleep duration was assessed by a single, parent-rated, open question, “How many hours 
does your child sleep per day including naps?” In GLAKU, parents were asked about the usual bed and rise times during school 
days, from which the total sleep duration could be estimated. 
 
